Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ES101 in Advanced Thoracic Malignancies (1b/2)
CTR20210749Phase 2Terminated
- Sponsor
- Elpiscience
- Start
- Apr 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of inbrx-105 in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), thoracic cancer, sponsored by Elpiscience. Started Apr 2021; status: terminated.
02
Drugs
inbrx-105
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)thoracic cancer
Beyond the preview
Go deeper on CTR20210749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210749.